This CPB on golimumab has been revised to: (i) remove age limitations for all golimumab (Simponi and Simponi Aria) indications; (ii) require that the prerequisite trial of methotrexate for rheumatoid arthritis (RA) be of at least 3-months’ duration; (iii) remove the requirement for a trial of another nonbiologic DMARD if methotrexate is contraindicated or not tolerated for treatment of RA; (iv) add examples of contraindications to methotrexate to the appendix; (v) add examples of contraindications to the use of NSAIDS to the appendix; (vi) add examples of conventional therapy options for ulcerative colitis (UC) to the appendix; (vii) add medical necessity criteria for continued use of golimumab; (viii) update the FDA-approved brands and indications for targeted immune modulators in the appendix, (ix) add dosing recommendations; and (x) restructure the medical necessity criteria nomenclature and format. This CPB has been revised to state that Simponi (golimumab for subcutaneous injection) is considered medically necessary for members who have a contraindication, intolerance or ineffective response to the least cost brands of targeted immune modulators for moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS) and axial spondyloarthritis, and moderately to severely active ulcerative colitis (UC). This CPB has been revised to remove fulminant disease as an indication for first line use of subcutaneous golimumab for ulcerative colitis.